AstraZeneca to supply Europe with up to 400 million doses of Oxford University's vaccine at no profit
- Details
- Category: AstraZeneca
AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford's COVID-19 vaccine, with deliveries starting by the end of 2020.
Gilead announces results from Phase 3 Trial of remdesivir in patients with moderate COVID-19
- Details
- Category: Gilead
Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label study evaluated 5-day and 10-day courses of the investigational antiviral remdesivir plus standard of care, versus standard of care alone.
Johnson & Johnson announces acceleration of its COVID-19 vaccine candidate; Phase 1/2a clinical trial to begin in second half of July
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.
New consortium EUbOPEN will provide tools to unlock disease biology
- Details
- Category: Boehringer Ingelheim
Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and disease-relevant processes is the use of well-characterized small chemical modulators of protein function.
AstraZeneca takes next steps towards broad and equitable access to Oxford University's COVID-19 vaccine
- Details
- Category: AstraZeneca
AstraZeneca has taken the next steps in its commitment to broad and equitable global access to the University of Oxford’s COVID-19 vaccine, following landmark agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII).
Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients
- Details
- Category: AstraZeneca
Results published in Science Immunology showed that Calquence (acalabrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor, reduced markers of inflammation and improved clinical outcomes of patients with severe COVID-19 disease.(1)
The peer-reviewed case series of 19 hospitalised patients with COVID-19 disease and severe hypoxia and/or inflammation is a collaboration from investigators across the US, including AstraZeneca scientists, and led by Wyndham Wilson, M.D., Ph.D. and Louis Staudt, M.D., Ph.D. at the National Cancer Institute of the National Institutes of Health in the US.
Bayer to support Harvard Research Study to evaluate trust in science, including in COVID-19 pandemic
- Details
- Category: Bayer
With the public debate on the merits of scientific data throughout the COVID-19 pandemic, Bayer announced its support for a new, multi-year Harvard Data Science Initiative (HDSI) research effort. This initiative will explore the public engagement with science, and better understand how to build confidence in the reliability, capability and integrity of scientific data and sound science.
More Pharma News ...
- Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
- Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration
- AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine
- Johnson & Johnson announces collaboration to expand manufacturing capabilities for its COVID-19 vaccine candidate
- Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program
- Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
- AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine